The spine company intends to use the proceeds to sustain global commercialization of its three minimally invasive products to treat degenerative disc disease with spinal fusion and vertebral compression fractures. It will also be used for additional initiatives to bring its fusion and VCF products to the U.S. market.
The three products include Benvenue Medical’s Kiva VCF Treatment System, Blazer Vertebral Augmentation System and Luna Interbody Spacer System.
More Articles on Orthopedic Devices:
Orthopedic Extremity Device Market to Surge Past $4.2B by 2016
Robert Wynalek Named Chief Operating and Commercialization Officer of Discgenics
NLT SPINE Reports Positive Clinical Results With PROW FUSION
